Gayatri

Garmin Files Patent for Smartwatch with Non-Invasive Blood Sugar Monitoring Technology

by

Garmin, a leading name in GPS and wearable technology, has filed a new patent that could significantly advance the future of digital health. The patent outlines a non-invasive blood glucose monitoring system integrated into its smartwatches, aiming to offer users a pain-free, continuous glucose tracking solution without the need for traditional finger-prick tests.

The innovation centers around light-based sensors, commonly referred to as photoplethysmography (PPG) or spectroscopy techniques, to analyze glucose levels through the skin. According to the patent documents, the smartwatch would emit specific wavelengths of light to penetrate the skin and detect variations in blood composition, including glucose concentration.

A Game-Changer in Glucose Monitoring

This development could be especially impactful for people managing diabetes or prediabetes, offering a convenient, non-invasive method for tracking blood sugar levels throughout the day. Unlike current continuous glucose monitors (CGMs) that typically require a sensor to be inserted under the skin, Garmin’s solution could eliminate the need for consumables or invasive procedures.

The system is expected to provide long-term trends and insights, allowing users to better understand how their lifestyle, diet, and activity levels affect their glucose metabolism. This aligns with Garmin’s broader strategy of expanding its health and wellness capabilities, reinforcing its position in a growing market that increasingly demands wearable-based health diagnostics.

Potential Capabilities Highlighted in the Patent

The patent describes the integration of a multi-sensor array capable of filtering out noise from other biological signals, such as heart rate or hydration levels, thereby improving the accuracy of glucose detection. The device could also work in tandem with Garmin’s suite of fitness metrics—like heart rate variability, sleep patterns, and stress monitoring—to deliver a comprehensive health profile.

While no official release timeline has been shared, Garmin’s entry into the blood glucose monitoring space reflects the broader trend of convergence between consumer electronics and medical diagnostics. Apple, Samsung, and several health tech startups have also been exploring similar non-invasive technologies, but commercial viability and clinical accuracy remain key challenges.

Regulatory and Market Implications

If Garmin’s device meets regulatory standards for accuracy and reliability, it could disrupt the global glucose monitoring market, currently valued at over $15 billion. Non-invasive solutions are considered the “holy grail” of diabetes care due to the convenience and user compliance they offer.

Experts suggest that Garmin may initially roll out the technology as a wellness feature before seeking FDA or CE approval for medical-grade use, a common approach in wearable health innovations.

Looking Ahead

Garmin’s patent marks a significant step forward in the evolution of smartwatches from fitness accessories to comprehensive health monitoring tools. As the race to develop non-invasive glucose tracking heats up, the company’s engineering strength and credibility in sensor technology may give it a competitive edge.

While the technology is still in the developmental stage, its potential to improve quality of life and promote preventive healthcare is immense, signaling a promising shift in the wearable tech landscape.

Hyderabad Cardiologist’s Groundbreaking Cardiac Device Wins US Patent

by
In a significant advancement for cardiac healthcare, an innovative medical device developed by Hyderabad-based pediatric cardiologist Dr. Nageswara Rao Koneti has been granted a United States patent. The invention, named the **KONAR-MF Occluder**, is designed to treat a wide range of congenital and acquired heart defects, making it a potential game-changer in cardiology worldwide.

Dr. Koneti, who leads the Cardiology Division at Rainbow Children’s Heart Institute in Hyderabad, spent over six years developing the KONAR-MF (Multi-Functional) Occluder. The device is engineered to close septal defects—abnormal openings in the heart—found in both children and adults.

At the heart of this innovation lies a **double umbrella disc structure** crafted from **nitinol**, a nickel-titanium alloy known for its flexibility and biocompatibility. The device is designed to be stretchable up to 15 mm, enabling it to adapt to varying defect sizes and shapes during minimally invasive procedures.

“This device can treat multiple complex cardiac conditions, including ventricular septal defects (VSDs), coronary arteriovenous fistulas, and paravalvular leaks,” said Dr. Koneti.

The KONAR-MF Occluder has already been recognized internationally. It holds patents in India, Europe (under the European Commission), several Euro-African countries, and South Korea. The addition of a U.S. patent not only underscores the global relevance of the device but also opens the door for broader clinical application and commercialization in North America.

Cardiologists often face challenges when dealing with complex septal defects due to the varying anatomical presentations and the need for precision closure to avoid complications. The KONAR-MF Occluder’s flexible and adaptive design seeks to address these clinical challenges by offering a reliable, minimally invasive solution.

“This is not just a win for me personally but a step forward for Indian medical innovation,” Dr. Koneti stated. “Our goal was to create a single device that could serve multiple purposes in cardiology, especially in regions where access to advanced medical infrastructure is limited.”

The device has already shown promising results in clinical trials, and further studies are being planned to evaluate long-term outcomes and expand its indications. With the U.S. patent secured, Dr. Koneti and his team hope to collaborate with global manufacturers and healthcare providers to bring this device into widespread use.

As congenital heart disease remains one of the most common birth defects globally, innovations like the KONAR-MF Occluder offer hope for safer, more effective treatments—especially in resource-limited settings. The global cardiology community will be watching closely as this device begins its journey into mainstream cardiac care.

BITS Law School Launches Centre for Research on Innovation Law for Shared Prosperity (CRISP); Hosts Inaugural Innovation Law & Policy Fellowship Conference

by

In a significant step toward fostering inclusive and future-oriented legal research, BITS Law School has announced the establishment of its Centre for Research on Innovation Law for Shared Prosperity (CRISP). The announcement was made during the inaugural conference of the Innovation Law & Policy Fellowship, held at the BITS Pilani Mumbai Campus.

The launch of CRISP marks a strategic move by BITS Law School to advance interdisciplinary research at the intersection of law, innovation, and equitable development. With India emerging as a global hub for technology and innovation, CRISP aims to explore how legal frameworks can support inclusive and sustainable progress.

The inaugural conference served as both a ceremonial and scholarly beginning for the Innovation Law & Policy Fellowship program. Distinguished legal scholars, industry leaders, policymakers, and research fellows convened to deliberate on how legal systems can evolve in response to rapid technological change while ensuring societal welfare.

Driving Innovation Through Law

Speaking at the event, Founding Dean of BITS Law School, Dr. Rishad Chowdhury, emphasized the role of CRISP in bridging the gap between legal theory and real-world policy challenges. “CRISP is not just a research centre; it is a catalyst for systemic transformation. Our goal is to equip policymakers and institutions with evidence-based insights that help balance innovation with justice, equity, and prosperity for all,” he said.

The centre will prioritize research in areas such as intellectual property, digital governance, biotechnology regulation, climate change law, and access to innovation in marginalized communities. Its core objective is to promote shared prosperity by making legal innovation inclusive and accessible.

Fellowship Program to Build Legal Talent for the Future

The Innovation Law & Policy Fellowship, launched in tandem with CRISP, seeks to nurture emerging legal thinkers committed to reimagining law for the innovation economy. The competitive fellowship offers early-career scholars an opportunity to engage in rigorous research under the mentorship of senior faculty and collaborate with national and international institutions.

Keynote addresses at the conference were delivered by prominent figures in the legal and technology sectors, including Justice (Retd.) Srikrishna, known for his pioneering work in data protection law, and Dr. Arundhati Bhattacharya, Chairperson of the India Digital Innovation Council. Their talks highlighted the urgent need for agile, responsive legal frameworks in the age of AI, data, and decentralized technologies.

A Vision for Inclusive Legal Futures

Participants at the conference discussed pressing challenges such as regulatory sandboxes for startups, innovation gaps in rural India, and global frameworks for equitable technology transfer. Panel sessions featured academics from top law schools, representatives from think tanks, and innovation-focused NGOs.

The event concluded with a roadmap presentation by the CRISP leadership team, outlining upcoming research themes, collaborative projects, and policy engagement initiatives.

About BITS Law School

Established under the aegis of the prestigious Birla Institute of Technology and Science (BITS), BITS Law School is a modern, interdisciplinary institution committed to reshaping legal education and policy-making in India. With CRISP now a part of its expanding research ecosystem, the law school reinforces its mission to contribute meaningfully to society through impactful legal research and advocacy.

As India navigates complex technological and societal shifts, the creation of CRISP positions BITS Law School as a thought leader in developing a legal infrastructure that promotes both innovation and equity.

KGMU Secures Design Patent for Innovative Infant Feeding Tube Uro Bag Connector

by

King George’s Medical University (KGMU) has achieved a significant milestone in pediatric healthcare innovation with the recent grant of a design registration patent for its newly developed Infant Feeding Tube (IFT) Uro Bag Connector. This novel device is designed to streamline the process of urine collection in newborns, a procedure that has historically posed considerable difficulties for healthcare professionals.

The patent, which was officially filed in February 2025, recognizes the unique design and utility of the connector developed by KGMU’s Department of Pediatrics in collaboration with biomedical engineers. The device enables the attachment of a standard adult uro bag to an infant feeding tube, thereby creating a secure and hygienic pathway for collecting urine from neonates.

Hospital officials highlighted that until now, urine collection in infants has remained a problematic area in clinical practice due to the lack of compatible systems. Traditional methods were not only cumbersome but also increased the risk of contamination and inaccuracies, often leading to repeated attempts and discomfort for the baby.

“The innovation addresses a longstanding gap in pediatric care,” said a senior KGMU pediatrician involved in the development. “Our design ensures a snug and sterile connection between the infant feeding tube and the uro bag, facilitating easier, safer, and more efficient urine collection.”

The device’s simplicity is one of its standout features. It eliminates the need for improvisation with existing equipment, which often led to unreliable setups and increased the burden on medical staff. With this connector, practitioners can now use readily available uro bags in a controlled and secure manner, reducing both procedural time and infection risks.

Officials from KGMU also emphasized the broader implications of the device, particularly in rural and resource-constrained healthcare settings. Since the connector utilizes components already commonly available in most hospitals, its adoption does not require additional infrastructural investment.

“This invention is not just a technological solution; it’s a step toward equitable and effective neonatal care,” said a spokesperson for the university’s innovation cell. “It exemplifies how simple yet thoughtful designs can transform clinical outcomes.”

The patent grant marks another feather in the cap for KGMU, which has been steadily expanding its footprint in medical research and innovation. The university is now exploring partnerships with manufacturers to produce the IFT-Uro Bag Connector at scale and make it widely accessible across healthcare institutions in India and potentially beyond.

With the successful patent registration, KGMU plans to initiate training modules and awareness campaigns to familiarize healthcare workers with the device, ensuring its effective integration into routine pediatric care.

Himachal Pradesh High Court Refuses to Quash FIR Against P&G in Patent Infringement Case

by

In a significant development in an ongoing intellectual property dispute, the Himachal Pradesh High Court has declined to quash a First Information Report (FIR) filed against multinational consumer goods giant Procter & Gamble (P&G). The case involves serious allegations of patent infringement and misuse of proprietary technology submitted under the company’s innovation partnership programme.

The FIR was lodged following a complaint by an Indian innovator who alleged that P&G misappropriated a patented innovation submitted as part of its well-known ‘Connect + Develop’ initiative — a global platform that invites inventors, startups, and researchers to collaborate with P&G by sharing innovative ideas and technologies for potential integration into P&G products.

Allegations of Misuse of Submitted Innovation

According to the complainant, after initial expressions of interest and discussions under the ‘Connect + Develop’ framework, P&G allegedly used the patented technology without entering into any formal agreement, licensing arrangement, or compensation. The innovation in question is believed to be integrated into one of P&G’s personal care products currently in the Indian market.

The innovator claims that the technology submitted was protected under Indian patent laws, and that its usage by P&G without authorization constitutes a direct violation of intellectual property rights.

Court’s Observations and Ruling

While hearing the petition seeking to quash the FIR, the Himachal Pradesh High Court observed that the matter involves disputed facts regarding intellectual property ownership, potential breach of trust, and alleged commercial exploitation. The court emphasized that such complex issues merit a thorough investigation and cannot be conclusively decided at the preliminary stage of quashing.

The court also highlighted that the ‘Connect + Develop’ programme, while promoting open innovation, must operate within the bounds of legal and ethical frameworks, especially when dealing with patented technologies.

P&G Responds

P&G has strongly denied any wrongdoing. In a brief statement, the company said:

“Procter & Gamble remains committed to ethical collaboration with external innovators. We respect intellectual property laws and take such matters seriously. We are cooperating fully with the authorities and are confident that the facts will vindicate our position.”

P&G also stressed that its ‘Connect + Develop’ platform has a longstanding reputation for transparency and fairness, having led to numerous successful collaborations globally.

Implications for Open Innovation Ecosystems

This case has raised broader questions about the protection of intellectual property in open innovation platforms, especially in scenarios where informal submissions may precede formal agreements. Legal experts suggest that innovators should take extra precautions when sharing patented or patent-pending technologies with corporate partners, even under programs intended to foster collaboration.

IP attorney Radhika Menon commented:

“This case underscores the importance of detailed documentation and non-disclosure agreements before disclosing any valuable intellectual property. Open innovation cannot be at the cost of the innovator’s rights.”

What Lies Ahead

The matter will now proceed through investigative channels, with law enforcement examining the chain of communication, documentation, and potential evidence of unauthorized usage. If proven, the case could set a precedent for how intellectual property is handled in corporate innovation programs, both in India and globally.

As the investigation unfolds, the case is being closely watched by innovators, legal experts, and corporates alike, serving as a cautionary tale about the fine balance between openness and protection in collaborative innovation.

New Toyota SUV Design Patent Hints at Revival of FJ Cruiser Spirit

by

Toyota is stirring excitement in the automotive world with a recently surfaced design patent that offers a first look at a new rugged SUV concept, which many believe could be the spiritual successor to the iconic FJ Cruiser. Filed in several global markets, including Japan and Australia, the patent reveals a boxy, robust design with retro-modern styling cues that harken back to Toyota’s heritage in off-road performance.

The patent images, which surfaced through official filings, suggest that the vehicle will be positioned beneath the globally popular Fortuner in Toyota’s SUV hierarchy. This places the yet-to-be-named SUV in a critical mid-range spot, likely targeting buyers seeking serious off-road capability without the size or premium price tag of the Fortuner or Land Cruiser.

A Nod to the FJ Cruiser Legacy

The design sketches display a bold front fascia featuring circular LED headlights housed in a squared-off grille, reminiscent of the original FJ Cruiser’s iconic face. Flared wheel arches, upright A-pillars, and short overhangs point toward a body-on-frame architecture designed for real-world off-road performance. At the rear, a tailgate-mounted spare tire and functional bumper design reinforce the SUV’s utilitarian roots.

While Toyota has not officially confirmed details about the model, the styling direction unmistakably channels the FJ Cruiser’s adventurous DNA — a vehicle that developed a cult following for its blend of retro looks and formidable 4×4 prowess before being discontinued in most markets nearly a decade ago.

Platform and Positioning

Industry analysts speculate that the new SUV may ride on Toyota’s TNGA-F platform, the same ladder-frame base that underpins the Hilux, Land Cruiser Prado, and Fortuner. This would provide the SUV with serious off-road credibility, while also supporting global scalability — a key consideration for Toyota as it aims to serve a wide spectrum of markets, from Southeast Asia and Australia to Latin America and Africa.

The vehicle is expected to be powered by Toyota’s new-generation powertrains, possibly including a downsized turbocharged petrol or diesel engine and a hybrid variant in select markets to meet tightening emissions norms and consumer demand for efficiency.

A Strategic Move in a Booming Segment

The compact and midsize SUV segment, especially those with off-road capability, is booming globally. Rivals like the Ford Bronco Sport, Suzuki Jimny, and Jeep Renegade Trailhawk have shown there’s strong consumer appetite for rugged, adventure-ready vehicles in a more manageable footprint.

For Toyota, introducing a smaller, rugged SUV would fill a noticeable gap in its current lineup — especially as the FJ Cruiser’s nostalgia remains strong among 4×4 enthusiasts and lifestyle adventurers. A modern interpretation of the FJ could allow Toyota to capture younger buyers and overlanders looking for a reliable, go-anywhere vehicle that doesn’t compromise on daily usability.

Global Outlook

Given Toyota’s recent focus on market-specific adaptations, the upcoming SUV may be tailored to meet regional preferences. While it is likely to launch first in markets where off-road vehicles remain a staple — such as Australia, South Africa, and parts of Southeast Asia — a global rollout could follow, depending on demand and regulatory approvals.

With Toyota expected to reveal more details later in 2025 or early 2026, anticipation is mounting for what could be one of the most exciting additions to the automaker’s SUV portfolio in years. If the final production model remains faithful to the patent sketches, Toyota could once again set a benchmark in the world of rugged, midsize utility vehicles.

India Bolsters Patent Processing Capacity Amid Global Surge in Intellectual Property Filings

by

India has significantly enhanced its patent processing capabilities, a strategic move aimed at fostering innovation and aligning with global standards in intellectual property (IP) administration. This development comes amid soaring patent activity worldwide, particularly in the United States and China, which continue to dominate the landscape of patent filings and grants.

According to data from the fiscal year 2023–24 (FY24), the United States granted approximately 3.15 lakh (315,000) patents out of 5.98 lakh (598,000) applications filed, indicating a strong approval rate and a robust IP infrastructure. Meanwhile, China granted an even more staggering 9.21 lakh (921,000) patents from a total of 16.78 lakh (1.678 million) filings. Despite the high volume, only about 3 lakh (300,000) of China’s granted patents are considered high quality, as clarified by Sanjeev Sanyal, Member of the Economic Advisory Council to the Prime Minister (EAC-PM).

Sanyal attributed this discrepancy in quality and efficiency to a key factor: manpower. “The quality and speed of patent processing are directly linked to the capacity and training of examiners. Countries that have invested heavily in human resources, such as the US and China, are reaping the benefits,” he noted during a recent policy discussion on India’s innovation ecosystem.

India, acknowledging this global trend and the strategic importance of a streamlined IP regime, has taken decisive steps to scale up its patent examination and processing capabilities. In recent years, the government has doubled down on recruiting and training patent examiners, improving infrastructure, and digitizing application processes through the Office of the Controller General of Patents, Designs and Trademarks (CGPDTM).

This effort is already showing signs of progress. In FY24, India witnessed a rise in patent grants and a reduction in the average time taken to process applications. While India’s absolute numbers still trail behind those of the US and China, the focus on quality over quantity is beginning to pay off. Intellectual property experts highlight that India’s patent grants are increasingly aligned with international standards, enhancing their enforceability and commercial value.

Sanyal emphasized that boosting IP processing is not just a bureaucratic necessity but a strategic imperative. “A well-functioning IP system encourages startups, attracts foreign investment, and promotes research and development. It’s about creating a virtuous cycle of innovation,” he said.

India’s aspirations to become a global innovation hub rest significantly on its ability to manage intellectual property efficiently. With the government’s concerted push and growing awareness among innovators and entrepreneurs, India is gradually strengthening its position in the global IP hierarchy.

As the world moves deeper into the knowledge economy, the capacity to process patents swiftly and with precision will be a key determinant of national competitiveness. India’s recent efforts, driven by both policy intent and institutional reform, suggest that the country is on the right path to meet this challenge head-on.

Global Supply Strains and Patent Clock Push Novo Nordisk into Tight Corner in India’s Obesity Drug Race

by
Novo Nordisk, the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy, is facing mounting challenges in India as it prepares to enter the burgeoning obesity treatment market. While the company has plans to launch Wegovy in India by 2026, it is grappling with global supply constraints and the impending expiration of its patent, which could open the floodgates for generic competition.

Global Supply Constraints
Novo Nordisk has acknowledged that global supply issues are affecting the availability of its GLP-1 receptor agonist drugs, including Wegovy and Ozempic. These medications have been in high demand due to their efficacy in weight loss and diabetes management. The company has been working to ramp up production to meet global needs, but the complexities of manufacturing and distribution have led to delays in some markets, including India.

Patent Expiry and Generic Competition
In India, the patent for semaglutide, the active ingredient in Wegovy, is set to expire in 2026. Companies like Biocon, Dr. Reddy’s Laboratories, and Cipla are already in the race to produce affordable alternatives, which could significantly impact Novo Nordisk’s market share in India. The Indian government’s Production-Linked Incentive (PLI) scheme is expected to further accelerate local manufacturing of these drugs, intensifying competition for Novo Nordisk.

Strategic Response
The company is also exploring partnerships with local manufacturers to enhance production capacity and ensure a steady supply of the drug. However, these efforts may be complicated by the ongoing global supply issues and the rapid development of generic alternatives by Indian companies.

Conclusion
As the patent expiry looms and competition intensifies, Novo Nordisk faces a critical juncture in its strategy for the Indian obesity drug market. The company’s ability to navigate global supply constraints and the emerging generic competition will determine its success in capturing market share in one of the world’s largest and fastest-growing pharmaceutical markets.

Dr. Reddy’s to Manufacture and Export Weight-Loss Drug, Semaglutide, but Not Sell in India, Informs Delhi HC

by
Dr. Reddy’s Laboratories has informed the Delhi High Court that it will manufacture and export the weight-loss drug semaglutide but will not sell it within India. This decision comes amid ongoing legal proceedings concerning patent rights and market exclusivity.

Background
Semaglutide, marketed globally as Ozempic and Wegovy by Danish pharmaceutical company Novo Nordisk, has gained significant attention for its effectiveness in weight management. In October 2023, Dr. Reddy’s received approval from India’s drug regulatory authority to conduct a bioequivalence study for semaglutide, aiming to establish its safety and efficacy for the Indian population. The company had initially sought a waiver for this study and a Phase III clinical trial but was advised by the Subject Expert Committee to proceed with the bioequivalence study .

Legal Developments
A significant legal confrontation emerged when Novo Nordisk filed a patent infringement lawsuit against Dr. Reddy’s Laboratories and OneSource Specialty Pharma, accusing them of unauthorized sales of semaglutide in the Indian market. In response, the Delhi High Court issued an order restraining both companies from selling the drug domestically until further notice. The next court hearing on the matter is scheduled for August 19, 2025 .
The Economic Times

Company’s Position
In light of these legal proceedings, Dr. Reddy’s has clarified that it will not engage in the sale of semaglutide within India. Instead, the company plans to manufacture the drug for export purposes, adhering to the provisions of Section 107A of the Indian Patents Act, which allows for the manufacture and export of patented drugs without infringing on the patent holder’s rights.

Industry Implications
The decision to manufacture and export semaglutide without selling it domestically highlights the complexities pharmaceutical companies face in navigating patent laws and market exclusivity. While Dr. Reddy’s aims to capitalize on the global demand for weight-loss medications, the ongoing legal challenges underscore the importance of securing patent rights and navigating regulatory approvals in each market.

Conclusion
As the legal proceedings continue, Dr. Reddy’s Laboratories remains committed to complying with Indian patent laws while exploring opportunities in international markets. The outcome of the upcoming court hearing will likely have significant implications for the company’s strategy concerning semaglutide in India.

Uber Faces Patent Lawsuit from Carma Technology Over Ride-Sharing Platform

by

Uber Technologies Inc. is currently facing a patent infringement lawsuit which is  filed by Carma Technology Corp. and Carma Technology Ltd. The lawsuit, initiated on January 14, 2025, in the U.S. District Court for the Eastern District of Texas, alleges that Uber’s ride-sharing platform infringes upon Carma’s patented technologies related to shared transportation systems. 

Details of the Lawsuit

Carma Technology, known for its innovations in ride-sharing solutions, holds several patents, including U.S. Patent No. US11574542B2, titled “Systems and methods for providing safety for drivers and riders in a shared transport system.”   The company claims that Uber’s platform utilizes technologies that infringe upon this and potentially other patents held by Carma.

The case, docketed as 2:2025cv00029, is presided over by District Judge Rodney Gilstrap.  Carma has demanded a jury trial, seeking damages and an injunction against Uber to prevent further alleged infringement. 

Potential Implications for Uber

If the court rules in favor of Carma Technology, Uber may face significant consequences, including financial penalties and the need to alter its ride-sharing platform to avoid further infringement.  Such changes could disrupt Uber’s operations and impact its position in the competitive ride-sharing market.

This lawsuit adds to Uber’s history of legal challenges related to intellectual property.  Notably, in 2018, Uber settled a lawsuit with Waymo, Alphabet Inc.’s self-driving car unit, agreeing to pay $245 million over allegations of trade secret theft. 

Broader Impact on the Ride-Sharing Industry

The outcome of this case could have broader implications for the ride-sharing industry.  A ruling favoring Carma Technology might prompt other companies to re-evaluate their platforms for potential patent infringements, leading to increased litigation and a push for innovation that respects existing intellectual property rights.

As the case progresses, stakeholders in the ride-sharing sector will be closely monitoring developments, understanding that the verdict could set a precedent affecting technology deployment and competitive dynamics in the industry.

*This article is based on publicly available information as of June 1, 2025.*